
For research use only. We do not supply to patients.
For pharmaceutical-grade products or other inquiries, please contact our experts.
Vasco RFV, et al. compared the effects of furosemide and hydrochlorothiazide on parameters of chronic kidney disease–mineral and bone disorder (CKD-MBD) in patients with stage 3 CKD followed for one year. Furosemide treatment resulted in increased bone remodeling and elevated parathyroid hormone (PTH) levels, suggesting stimulation of bone turnover. In contrast, hydrochlorothiazide attenuated the rise in PTH and decreased bone turnover markers. These divergent effects reflect the distinct mechanisms of action of loop versus thiazide diuretics on calcium handling and mineral metabolism.
Fig. 1 Effect of diuretic type on PTH 1-84 and bone biomarkers. (Vasco RFV, et al., 2021)
References
Vaculikova E, et al. conducted a pharmaceutical development study aimed at improving the solubility of hydrochlorothiazide, a Class IV Biopharmaceutical Classification System drug, through nanoparticle formulation. Using antisolvent precipitation–solvent evaporation and emulsion solvent evaporation methods with various surfactants, the researchers successfully prepared 18 nanoparticle samples. The optimal formulation, stabilized with 5% carboxymethyl dextran sodium salt, achieved a particle size of 2.6 nm and demonstrated 6.5-fold higher solubility compared to bulk hydrochlorothiazide.
Fig. 2 SEM images of bulk hydrochlorothiazide at magnification 1600× (A) and hydrochlorothiazide stabilized with 5% carboxymethyl dextran sodium salt at magnification 100× (B). (Vaculikova E, et al, 2016)
References
Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed
All our products are chemicals for research purposes only. We do not supply for human or veterinary applications.
Privacy Policy | Cookie Policy Copyright © Protheragen. All Rights Reserved.
